Dimensional Fund Advisors
CRSP icon

Dimensional Fund Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Dimensional Fund Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.3M Sell
259,016
-16,359
-6% -$883K ﹤0.01% 2154
2026
Q2 		$15M Sell
275,375
-218,843
-44% -$11.5M ﹤0.01% 2157
2026
Q1 		$23.5M Sell
494,218
-412,889
-46% -$21.8M ﹤0.01% 1893
2025
Q4 		$47.6M Buy
907,107
+30,078
+3% +$1.8M 0.01% 1536
2025
Q3 		$56.8M Sell
877,029
-40,683
-4% -$2.34M 0.01% 1445
2025
Q2 		$44.6M Sell
917,712
-19,433
-2% -$752K 0.01% 1564
2025
Q1 		$31.9M Sell
937,145
-10,156
-1% -$431K 0.01% 1715
2024
Q4 		$37.3M Buy
947,301
+122,695
+15% +$5.79M 0.01% 1687
2024
Q3 		$38.7M Sell
824,606
-125,543
-13% -$6.37M 0.01% 1656
2024
Q2 		$51.3M Buy
950,149
+19,094
+2% +$1.1M 0.01% 1452
2024
Q1 		$63.5M Buy
931,055
+151,601
+19% +$10.9M 0.02% 1293
2023
Q4 		$48.8M Sell
779,454
-100,347
-11% -$5.55M 0.01% 1464
2023
Q3 		$39.9M Buy
879,801
+168,530
+24% +$8.7M 0.01% 1494
2023
Q2 		$39.9M Sell
711,271
-48,464
-6% -$2.75M 0.01% 1509
2023
Q1 		$34.4M Buy
+759,735
New +$36.9M 0.01% 1604
2022
Q3 		$42.4M Buy
649,060
+209,134
+48% +$15.2M 0.02% 1363
2022
Q2 		$26.7M Buy
439,926
+199,939
+83% +$11.8M 0.01% 1698
2022
Q1 		$15.1M Sell
239,987
-19,054
-7% -$1.2M ﹤0.01% 2120
2021
Q4 		$19.6M Buy
259,041
+104,371
+67% +$9.12M 0.01% 1998
2021
Q3 		$17.3M Buy
154,670
+8,848
+6% +$1.11M 0.01% 2073
2021
Q2 		$23.6M Buy
145,822
+7,072
+5% +$860K 0.01% 1974
2021
Q1 		$16.9M Buy
138,750
+31,103
+29% +$4.7M 0.01% 2091
2020
Q4 		$16.5M Buy
107,647
+5,990
+6% +$708K 0.01% 2071
2020
Q3 		$8.5M Buy
101,657
+645
+0.6% +$57.2K ﹤0.01% 2268
2020
Q2 		$7.42M Buy
101,012
+12,527
+14% +$732K ﹤0.01% 2319
2020
Q1 		$3.75M Buy
88,485
+41,952
+90% +$2.17M ﹤0.01% 2517
2019
Q4 		$2.83M Buy
+46,533
New +$2.54M ﹤0.01% 2767

Other funds holding CRSP

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
EverSource Wealth Advisors
EverSource Wealth Advisors Birmingham, Alabama $3.11B AUM 21.48% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Slow Capital
Slow Capital Greenbrae, California $890M AUM 40.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
State of Michigan Retirement System
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 32.98% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Dimensional Fund Advisors's CRSP Position: Q3 2026 in Review

Dimensional Fund Advisors reduced its CRISPR Therapeutics (CRSP) stake by 5.9% in Q3 2026, selling an estimated $883K and leaving 259,016 shares worth $14.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2154.

Dimensional Fund Advisors first reported a position in CRSP in Q4 2019 and has held it in 27 quarters since. The position peaked at $63.5M in Q1 2024. 201 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Dimensional Fund Advisors held 259,016 shares of CRISPR Therapeutics worth $14.3M as of Q3 2026.
  • Dimensional Fund Advisors sold 16,359 CRISPR Therapeutics shares in Q3 2026, an estimated $883K.
  • CRISPR Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #2154 holding.
  • Dimensional Fund Advisors first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • Dimensional Fund Advisors's CRISPR Therapeutics position peaked at $63.5M in Q1 2024.
  • 201 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.